NasdaqGS - Nasdaq Real Time Price USD
Zenas BioPharma, Inc. (ZBIO)
9.91
+0.10
+(1.07%)
At close: 4:00:01 PM EDT
9.91
0.00
(0.00%)
After hours: 4:19:59 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 0 | 0 |
| Sales | -- | 0 |
| Net Shares Purchased (Sold) | 0 | 0 |
| Total Insider Shares Held | 10.36M | -- |
| % Net Shares Purchased (Sold) | -- | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| MOULDER LEON OLIVER JR. Chief Executive Officer | Purchase at price 6.67 per share. | Direct | 166,750 | Feb 18, 2025 |
| XIAO TING Director | Purchase at price 7.76 per share. | Direct | 77,600 | Feb 7, 2025 |
| MOULDER LEON OLIVER JR. Chief Executive Officer | Purchase at price 9.98 - 10.76 per share. | Direct | 718,100 | Dec 4, 2024 |
| MOULDER LEON OLIVER JR. Chief Executive Officer | Purchase at price 14.57 - 15.00 per share. | Direct | 148,925 | Nov 19, 2024 |
| MOULDER LEON OLIVER JR. Chief Executive Officer | Purchase at price 17.88 - 18.97 per share. | Indirect | 360,820 | Sep 20, 2024 |
| ENRIGHT PATRICK G. Director | Purchase at price 17.00 per share. | Indirect | 7,480,000 | Sep 16, 2024 |
| ENRIGHT PATRICK G. Director | -- | Indirect | -- | Sep 16, 2024 |
| MOULDER LEON OLIVER JR. Chief Executive Officer | -- | Indirect | -- | Sep 16, 2024 |
| MOULDER LEON OLIVER JR. Chief Executive Officer | -- | Indirect | -- | Sep 16, 2024 |
| NUNN JASON RALEIGH Director | Purchase at price 17.00 per share. | Indirect | 14,999,984 | Sep 16, 2024 |
| NUNN JASON RALEIGH Director | -- | Indirect | -- | Sep 16, 2024 |
| SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | Indirect | 37,999,998 | Sep 16, 2024 |
| SR ONE CAPITAL MANAGEMENT, LLC Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Sep 16, 2024 |
| WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS CAYMAN I L Beneficial Owner of more than 10% of a Class of Security | -- | Direct | -- | Sep 16, 2024 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Director | Purchase at price 17.00 per share. | Indirect | 5,100,000 | Sep 16, 2024 |
| FAIRMOUNT FUNDS MANAGEMENT LLC Director | -- | Indirect | -- | Sep 16, 2024 |
| ENAVATE SCIENCES GP, LLC Beneficial Owner of more than 10% of a Class of Security | Purchase at price 17.00 per share. | Indirect | 15,000,001 | Sep 16, 2024 |
| ENAVATE SCIENCES GP, LLC Beneficial Owner of more than 10% of a Class of Security | -- | Indirect | -- | Sep 16, 2024 |
| LU HONGBO B Director | Purchase at price 17.00 per share. | Indirect | 999,991 | Sep 13, 2024 |
Related Tickers
MBX MBX Biosciences, Inc.
8.99
+4.05%
SION Sionna Therapeutics, Inc.
13.09
+9.72%
RCUS Arcus Biosciences, Inc.
8.11
+0.25%
UPB Upstream Bio, Inc.
8.81
-13.20%
GYRE Gyre Therapeutics, Inc.
9.19
+6.37%
BCAX Bicara Therapeutics Inc.
15.51
+12.23%
KYTX Kyverna Therapeutics, Inc.
2.1300
+1.43%
ALMS Alumis Inc.
4.7100
-5.23%
CGON CG Oncology, Inc.
20.73
+1.22%
MLYS Mineralys Therapeutics, Inc.
13.53
+2.42%